EcoDrugPlus

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSBTAG00000020048
Gene Symbol: MAPK10
31 Enzyme and pathways 5 Cross references
234 Possible Orthologues:

Mitogen-Activated Protein Kinase 11

Ensembl ID : ENSBTAG00000030182
Gene Symbol: MAPK11
58 Enzyme and pathways 5 Cross references
211 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSBTAG00000020783
Gene Symbol: MAPK14
65 Enzyme and pathways 5 Cross references
302 Possible Orthologues:

Mitogen-Activated Protein Kinase 3

Ensembl ID : ENSBTAG00000016156
Gene Symbol: MAPK3
120 Enzyme and pathways 5 Cross references
211 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSBTAG00000007876
Gene Symbol: MAPK8
53 Enzyme and pathways 5 Cross references
304 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSBTAG00000004709
Gene Symbol: MAPK9
31 Enzyme and pathways 5 Cross references
231 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSBTAG00000033983
Gene Symbol: MAP2K1
21 Enzyme and pathways 5 Cross references
223 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSBTAG00000024450
Gene Symbol: MAP2K2
21 Enzyme and pathways 5 Cross references
281 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSBTAG00000013790
Gene Symbol: MAP3K1
24 Enzyme and pathways 5 Cross references
172 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSBTAG00000017618
Gene Symbol: MAP3K10
5 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSBTAG00000004114
Gene Symbol: MAP3K11
10 Enzyme and pathways 5 Cross references
196 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSBTAG00000020758
Gene Symbol: MAP3K12
5 Cross references
266 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).